Open Access

The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients

  • Authors:
    • Juan Zhou
    • Guoping Niu
    • Yunfeng Pei
    • Chunping Cao
    • Chen Ding
    • Guangming Sun
    • Jing Guo
    • Yong Liu
    • Yang Yu
  • View Affiliations

  • Published online on: August 29, 2016     https://doi.org/10.3892/ol.2016.5055
  • Pages: 3191-3194
  • Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim was to investigate the clinical efficacy and immunomodulatory effect of lienal polypeptide injection combined with postoperative FOLFOX chemotherapy regimen in colon cancer patients. A total of 84 colon cancer patients were selected between January, 2014 and December, 2015. The selected patients were randomly divided into the observation (42 patients) and control (42 patients) groups. The observation group patients were treated with FOLFOX chemotherapy regimen combined with lienal polypeptide, whereas, the control group patients were treated with FOLFOX chemotherapeutic regimen only. After two cycles of treatment, Karnofsky performance scale (KPS) index, side effects or toxicity and the peripheral blood T‑cell subset analyses in the two groups of patients were evaluated. The patients who received FOLFOX chemotherapeutic regimen combined with lienal polypeptide in the observation group showed significantly higher score of KPS than patients of the control group (P<0.05). No significant difference in the spectrum of side effects such as nausea, vomiting, neurotoxicity, liver and kidney dysfunction, oral mucosal inflammation were observed in the treatment groups. However, the incidence of bone marrow suppression was significantly lower in the observation group in comparison with the control group (P<0.05). Additionally, the CD8+ T cells were decreased in the observation group patients compared to the control group, while the ratio of CD4+ T/CD8+ T (TH/TC) cells and the number of natural killer cells were higher in the observation group patients than the control group (P<0.05). In conclusion, the results suggest that, when the standard FOLFOX chemotheraputic regimen is combined with lienal polypeptide to treat colon cancer, it enhances the general well being of patients and strengthens the immune system in the combat against cancer.
View References

Related Articles

Journal Cover

November-2016
Volume 12 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou J, Niu G, Pei Y, Cao C, Ding C, Sun G, Guo J, Liu Y and Yu Y: The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients. Oncol Lett 12: 3191-3194, 2016
APA
Zhou, J., Niu, G., Pei, Y., Cao, C., Ding, C., Sun, G. ... Yu, Y. (2016). The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients. Oncology Letters, 12, 3191-3194. https://doi.org/10.3892/ol.2016.5055
MLA
Zhou, J., Niu, G., Pei, Y., Cao, C., Ding, C., Sun, G., Guo, J., Liu, Y., Yu, Y."The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients". Oncology Letters 12.5 (2016): 3191-3194.
Chicago
Zhou, J., Niu, G., Pei, Y., Cao, C., Ding, C., Sun, G., Guo, J., Liu, Y., Yu, Y."The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients". Oncology Letters 12, no. 5 (2016): 3191-3194. https://doi.org/10.3892/ol.2016.5055